N/A N=194 Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Bridge to Cardiac Transplantation
Heart Failure, Congestive · Ventricular Dysfunction · Cardiomyopathies
Primary: Survival — 112; 6; 18; 19 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=639 Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure
Chronic Heart Failure
Primary: The Primary Endpoint is Success at 180 Days Which is Defined as Alive on the Originally Implanted HeartWare® LVAD or Transplanted or Explanted for Recovery. Patient Must…
N/A N=75 International EXPAND Heart Pivotal Trial
Heart Transplant
Primary: Patient Survival at Day-30 Post Transplant and Absence of Severe Primary Heart Graft Dysfunction in the First 24 Hours Post-transplantation — 66 Participants — p=<0.0001
N/A N=72 Don't Throw Your Heart Away: Clinician Study 3
Cardiac Transplant Disorder
Primary: Hospital Choice — 4; 21; 34; 13 Participants
Phase 3 N=22 Coronary Artery Vasculopathy in Pediatric Heart Transplant Patients
Orthotopic Heart Transplant
Primary: Coronary Flow Reserve (CFR) — 1.77 ratio: peak to baseline CFV
N/A N=180 Donors After Circulatory Death Heart Trial
Heart Transplant
Primary: Survival — 76; 75 Participants — p=<0.0001
N/A N=90 Donor After Circulatory Death Heart CAP Trial
Heart Transplant
Primary: Patient Survival — 75 Participants
Phase 4 N=25 HCV Positive Heart Donors
Heart Failure
Primary: Sustained Virologic Response After Treatment — 24 Participants
N/A N=200 Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Destination Therapy
Heart Failure, Congestive · Ventricular Dysfunction · Cardiomyopathies
Primary: Composite Endpoint — 46; 11 percentage of participants — p=0.00000025
N/A N=177 Diabetes and Lipid Accumulationand Heart Transplant
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
N/A N=75 Heart EXPAND Continued Access Protocol
Heart Transplant
Primary: Patient Survival at Day 30 Post-transplantation and Absence of Severe PGD (Left or Right Ventricle) in the First 24 Hours Post-transplantation — 72 Participants
Phase 1 N=14 Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single Ventricle Physiology
Hypoplastic Left Heart Syndrome · Single Ventricle · Heart Failure
Primary: Feasibility Evaluation and Major Cardiac Adverse Events Related to Transcoronary Infusion of Cardiac Progenitor Cells — 0; 0 participants
N/A N=6 Clinical Evaluation of HW005 Ventricular Assist System for the Treatment of Advanced Heart Failure in Japan
Heart Failure
Primary: Number of Participants Alive on the Implanted HW005 Ventricular Assist System or Transplanted or Explanted for Recovery at 180 Days — 6 Participants
N/A N=446 The HeartWare™ Ventricular Assist System as Destination Therapy of Advanced Heart Failure: the ENDURANCE Trial
Chronic Heart Failure
Primary: Stroke-Free Survival Probability for 2 Years Post Implant — 55.4; 59.1 Probabillity — p=0.0110
Phase 2 N=20 Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)
Heart Failure
Primary: Number of Participants With Post-treatment Sustained Virologic Response (SVR) — 9 Participants
Phase 3 N=36 The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
Antibody-mediated Rejection · Hyperacute Rejection of Cardiac Transplant · Left Ventricular Dysfunction
Primary: Number of Participants of Pathologic Antibody-Mediated Rejection and Left Ventricular Dysfunction — 4 Participants
Phase 3 N=838 Intravenous Thyroxine for Heart-Eligible Organ Donors
Brain Death · Heart Failure
Primary: Heart Transplanted — 230; 223 Participants — p=0.57
Phase 2 N=65 The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)
Stem Cell Transplantation · Ventricular Dysfunction, Left
Primary: Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade…
N/A N=96 Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy
Cardiac Allograft Vasculopathy
Primary: Cardiac Allograft Vasculopathy(CAV) Defined as Change in IVUS-assessed Plaque Volume From Baseline to One Year — 3.39; 3.65 mm3/mm
N/A N=101 Post- Approval Study on Patients Who Received a HeartWare HVAD® During IDE Trials
Heart Failure
Primary: Overall Survival on Device — 52.9 Percent Probability of Survival
N/A N=105 Don't Throw Your Heart Away: Medical Student Study 2
Cardiac Transplant Disorder
Primary: Hospital Choice — 33; 47; 23; 2 Participants
Phase 4 N=30 Transepicardial With Transseptal Autologous CD 133+ Bone Marrow Cell Implantation in Patient Following CABG Surgery
Coronary Artery Disease
Primary: Myocardial Defect Perfusion — 15.76; 15.38; 2.08; 3.85 Percentage of Myocardial Perfusion
N/A N=1,019 Don't Throw Your Heart Away: Layperson Study 1
Cardiac Transplant Disorder
Primary: Hospital Choice — 64; 125; 163; 192 Participants
Phase 3 N=102 Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients
Heart Transplant Recipients
Primary: Peak Oxygen Consumption — 23.9; 22.0 ml/kg/min
Phase 2 N=20 Hyperbaric Oxygen Therapy for Lung Transplantation
Disorder Related to Lung Transplantation · Central Airway Stenosis · Airway Exudative Plaques
Primary: Subjects Needing Airway Stent Placement as Determined by Transbronchial Lung Biopsy. — 4; 4 Participants — p=1
Phase 4 N=115 SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance
Renal Function and Chronic Allograft Vasculopathy
Primary: Measured Glomerular Filtration Rate (mGFR), 12 Months After Heart Transplantation — 79.8; 61.5 mGFR ml/min
Phase 2 N=25 Stem Cell Therapy in Patients With Severe Heart Failure & Undergoing Left Ventricular Assist Device Placement
Heart Failure
Primary: Safety of Cell Delivery — 1; 0 adverse events
Phase 2 N=10 Transplanting Hepatitis C Lungs Into Negative Lung Recipients
Lung Diseases
Primary: Subject Sustained Virologic Response (SVR-12) at 12-weeks Post-treatment — 10 Participants
Phase 3 N=109 Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens
Heart Diseases · Heart Transplantation
Primary: The Change in the Markers of Growth, Apoptosis, Inflammation and Oxidation Measured in Endomyocardial Biopsies — 0.70; 0.90; 0.87; 0.79 Densitometry / Densitometry of…
Phase 2 N=18 Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation
Cardiac Allograft Vasculopathy
Primary: Insulin Levels Area Under Curve(AUC) — -47.7; 10.7 h*pmol/L